Cognitive Stimulation for Elderly Bipolar Patients
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65+
SponsorGroupe Hospitalier de la Rochelle Ré Aunis
About this trial
Age is a major risk factor for the development of cognitive disorders and neurodegenerative pathologies. Cognitive disorders during the phases of bipolar disease are known to exist, and alterations increase significantly after the age of 65. Drug treatments seem to have only a limited effect. A cognitive stimulation program has proven his benefit to patients over 65 with neurodegenerative diseases (Israel, 2004). We propose to evaluate this cognitive stimulation program that we have adapted to bipolar disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age > 65 years old
Diagnosis of bipolar illness for more than 10 years
Euthymic phase
Understands and speaks French
Disqualifiers
Illiteracy
Patient participating in other therapeutic workshops (e. g. psycho-geriatric day hospital care, etc.)
Persons deprived of their liberty by a judicial or administrative decision
Persons of full age who are subject to a legal protection measure
Trial design
Design model
Parallel
Treatments tested in this trial
cognitive stimulation
BehavioralPatients participate in one session per week according to the following schedule: * 2 sensory stimulation sessions: identify sensations, emotions, how to manage them. * 2 sessions on association, verbal fluency, and imagination: language as a tool for expression in the face of illness. * 2 voluntary attention sessions: improve daily attention. * 2 sessions of intellectual structuring: stimulating and maintaining memory, carrying out external activities. * 2 sessions of structuring through language: impact on social life. * 2 sessions stimulating the temporal and spatial landmarks: agenda, daily trips.
Treatment groups
40 Participants
are divided into 2 treatment groupsGroup A: TONICExperimental treatment 1 intervention
Group B: ControlNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Score at the Frontal Assessment Battery (FAB)
The FAB assesses conceptualization (category responses, such as "in what way are a banana and an orange are alike?"), lexical fluency, programming or motor series (Luria), sensitivity to interference (conflicting instructions, such as "tap twice when I tap once"), inhibitory control (Go/No-Go), and environmental autonomy (prehension behavior, such as "do not take my hands")
Time frame
at 3 months after inclusionSecondary outcomes
1
Score at FAB
Scores between the 3-month and 6-month evaluation will determine whether executive analysis functions have been maintained
Time frame
at 6 months after inclusion2
Number of patients with a positive difference between the scores on the Functional Activities Questionnaire (QAF)
The QAF allows to quickly assess a patient's functional capacity and to identify a functional decline in the patient with a mild neurocognitive disorder, Alzheimer's disease or other neurocognitive disorder.
Time frame
at inclusion3
Number of patients with a positive difference between the scores on the Functional Activities Questionnaire (QAF)
A positive difference in scores reflects an improvement in patient autonomy
Time frame
at 6 months after inclusion4
Score at delayed matching-to-sample (DMS48)
The DMS48 is a test of visual recognition memory test
Time frame
at inclusionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov